| P50 | author | Praveen Papareddy | Q58658896 |
| | Ravi K V Bhongir | Q85276206 |
| P2093 | author name string | Artur Schmidtchen | |
| | Martin Malmsten | |
| | Matthias Mörgelin | |
| | Martina Kalle | |
| | Gopinath Kasetty | |
| P2860 | cites work | Host defense peptides of thrombin modulate inflammation and coagulation in endotoxin-mediated shock and Pseudomonas aeruginosa sepsis | Q27331817 |
| | Responses of Pseudomonas aeruginosa to antimicrobials | Q28305587 |
| | Highly selective end-tagged antimicrobial peptides derived from PRELP | Q28476835 |
| | Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies | Q29617810 |
| | Proteolysis of human thrombin generates novel host defense peptides | Q29871443 |
| | High-throughput generation of small antibacterial peptides with improved activity | Q33220258 |
| | Evaluating different descriptors for model design of antimicrobial peptides with enhanced activity toward P. aeruginosa | Q33293383 |
| | A peptide of heparin cofactor II inhibits endotoxin-mediated shock and invasive Pseudomonas aeruginosa infection. | Q33927961 |
| | Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial | Q34518326 |
| | Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances | Q34750112 |
| | Antithrombin: a new look at the actions of a serine protease inhibitor | Q35004303 |
| | The TFPI-2 derived peptide EDC34 improves outcome of gram-negative sepsis. | Q35067228 |
| | Antibacterial peptides for therapeutic use: obstacles and realistic outlook | Q36556909 |
| | Proteolytic activation transforms heparin cofactor II into a host defense molecule | Q36914757 |
| | Host-pathogen interactions in sepsis | Q37026360 |
| | Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells | Q37628594 |
| | Activation of the complement system generates antibacterial peptides | Q37695583 |
| | Novel therapeutic strategies to counter Pseudomonas aeruginosa infections. | Q37984505 |
| | Modulating immunity as a therapy for bacterial infections | Q37994068 |
| | Cationic host defence peptides: multifaceted role in immune modulation and inflammation. | Q38022156 |
| | Sepsis and thrombosis | Q38102642 |
| | Immune modulation by multifaceted cationic host defense (antimicrobial) peptides | Q38162670 |
| | New perspectives in the management of Pseudomonas aeruginosa infections | Q38243221 |
| | Importance of lipopolysaccharide aggregate disruption for the anti-endotoxic effects of heparin cofactor II peptides | Q39134176 |
| | P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients | Q39479122 |
| | Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure | Q40407531 |
| | Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group | Q40638967 |
| | The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group | Q40653300 |
| | Antimicrobial effects of helix D-derived peptides of human antithrombin III | Q41747279 |
| | Antibacterial agents based on the cyclic D,L-alpha-peptide architecture | Q44022306 |
| | Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group | Q44267568 |
| | Antimicrobial activities of heparin-binding peptides | Q44629787 |
| | Ultrasensitive assays for endogenous antimicrobial polypeptides | Q45416239 |
| | Rational design of antimicrobial C3a analogues with enhanced effects against Staphylococci using an integrated structure and function-based approach | Q46438108 |
| | Domain 5 of high molecular weight kininogen is antibacterial | Q46642869 |
| | Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections | Q46726010 |
| | Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group | Q46886444 |
| | Preservation of antimicrobial properties of complement peptide C3a, from invertebrates to humans. | Q47831006 |
| | Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. | Q53753081 |
| | Antimicrobial peptides derived from growth factors. | Q54442631 |
| | Bacterial killing by heparin-binding peptides from PRELP and thrombospondin. | Q54464584 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Pseudomonas aeruginosa | Q31856 |
| | antimicrobial peptide | Q1201508 |
| P304 | page(s) | 170-180 | |
| P577 | publication date | 2015-10-26 | |
| P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
| P1476 | title | NLF20: an antimicrobial peptide with therapeutic potential against invasive Pseudomonas aeruginosa infection | |
| P478 | volume | 71 | |